Hepatitis B antiviral agents

Inventors

Qiu, Yao-Ling • Gao, Xuri • Kass, Jorden • Cao, Hui • Li, Wei • Peng, Xiaowen • Suh, Byung-Chul • Or, Yat Sun

Assignees

Enanta Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12496282-B2

Patent

Publication Date

2025-12-16

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Core Innovation

The disclosure describes Formula (I) compounds functioning as hepatitis B virus core and capsid modulators that disrupt capsid assembly, disassembly, maturation, and interactions with viral components, viral DNA, reverse transcriptase, or host partners. These antiviral agents reduce viral infectivity and viral load, while potentially affecting cccDNA. An independent claim covers a method of treating hepatitis B virus infection using a formula-defined compound wherein R is hydrogen or fluorine together with specified therapeutic agents.

The disclosed chemical space encompasses substituted bicyclic sulfone-containing analogs, including substituted sulfone-containing benzamides and hydroxylated bicyclo[3.2.1]octane sulfone benzamides bearing aryl, amide, ether, and heterocyclic substituents. Screening results demonstrate anti-HBV activity in HepAD38 cells alongside cytotoxicity evaluations. The description further details pharmaceutical compositions and methods of administration for monotherapy and combination treatment targeting hepatitis B virus infection.

Claims Coverage

The claims identify one independent claim directed to a method of treating hepatitis B virus infection, comprising two inventive features.

Combination treatment of hepatitis B virus infection with formula-defined compound

A method of treating a hepatitis B virus infection in a subject in need thereof, comprising administering a therapeutically effective amount of a compound represented by the formula wherein R is hydrogen or fluorine, together with a therapeutic agent selected from the group consisting of viral entry inhibitors, capsid assembly modulators, reverse transcriptase inhibitors, and TLR agonists.

Specified therapeutic agent subclasses

Administering specified therapeutic agents, wherein dependent claims further specify reverse transcriptase inhibitors and TLR agonists, including listed candidate agents.

The claims cover combination treatment of hepatitis B virus infection using a specified formula-defined compound wherein R is hydrogen or fluorine together with an agent selected from four specified therapeutic classes, with dependent claims specifying candidate agents.

Stated Advantages

The compounds are described as reducing HBV infectivity and viral load.

The compounds are described as potentially affecting HBV cccDNA.

The compounds are asserted to have potential activity against drug-resistant strains and potential reductions in treatment duration or resistance.

Documented Applications

Treatment of hepatitis B virus infection in a subject in need thereof using the claimed compound together with a therapeutic agent selected from viral entry inhibitors, capsid assembly modulators, reverse transcriptase inhibitors, or TLR agonists.

Monotherapy and combination treatment for hepatitis B virus infection, including combinations with antiviral and immune-modulating agents in pharmaceutical compositions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.